Clinical and Analytical Performance of the Liaison Cardiac Troponin I Assay in Unstable Coronary Artery Disease, and the Impact of Age on the Definition of Reference Limits. A FRISC-II Substudy
- 1 June 2003
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 49 (6) , 880-886
- https://doi.org/10.1373/49.6.880
Abstract
Background: Measurements of cardiac troponins are currently used as the standard for the detection of myocardial injury. None of the current assays complies with the new requirements on assay imprecision as proposed by the European Society of Cardiology/American College of Cardiology. Our aim was to evaluate the clinical and analytical performance of the Liaison cardiac troponin I (cTnI) assay. Methods:EDTA-plasma was used, and cardiac troponins were assayed with the first-generation AxSYM assay, the second-generation AccuTnI assay, the third-generation Elecsys assay, and the first-generation Liaison assay. Results: In a 6-day imprecision study, the Liaison cTnI assay had mean CV ≤10% at 0.027 μg/L and ≤20% at 0.015 μg/L. The 99th percentile of the upper reference limit (URL) of a reference population was 0.041 μg/L (age range, 41–76 years). Individuals P = 0.001) lower 99th percentile, 0.022 μg/L. The FRISC-II study participants with cTnI ≥0.041 μg/L had a poorer outcome relating to death/acute myocardial infarction than those with cTnI P 0.041 μg/L (P = 0.002 and 0.02, respectively). Comparison with the AccuTnI assay showed that a large cohort of the patients with poor prognosis was identified by the AccuTnI assay but not by the Liaison cTnI assay. Conclusion: The Liaison cTnI assay is a sensitive assay with a CV ≤10% at the 99th percentile URL. The ability to detect age-related differences among apparently healthy individuals is unique among today’s commercial assays. The results indicate that different assays seem to identify different patient cohorts for cardiac risk in the lower range of cTnI concentrations.Keywords
This publication has 22 references indexed in Scilit:
- Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy)The American Journal of Cardiology, 2002
- Determination of cardiac troponin I forms in the blood of patients with unstable angina pectorisClinical Biochemistry, 2002
- Extensive Troponin I and T Modification Detected in Serum From Patients With Acute Myocardial InfarctionCirculation, 2000
- Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarctionJournal of the American College of Cardiology, 2000
- Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trialThe Lancet, 2000
- Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: Proposed revisionsAmerican Heart Journal, 2000
- Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre studyThe Lancet, 1999
- Applicability of Cardiac Troponin T and I for Early Risk Stratification in Unstable Coronary Artery DiseaseCirculation, 1997
- Troponin T Identifies Patients With Unstable Coronary Artery Disease Who Benefit From Long-Term Antithrombotic ProtectionJournal of the American College of Cardiology, 1997
- Relation Between Troponin T and the Risk of Subsequent Cardiac Events in Unstable Coronary Artery DiseaseCirculation, 1996